ALKBH5 and non-small cell lung carcinoma: By altering ALKBH5 activity or blocking its interaction with circEML4, researchers reduced SOCS2 regulation via m6A modification, thereby inhibiting JAK-STAT pathway activation and slowing NSCLC progression (131).